Form 4: Pliant Therapeutics Director David Pyott Granted 30,000 Stock Options

Pliant Therapeutics, Inc. Director David E.I. Pyott was granted 30,000 stock options with an exercise price of $1.61, vesting over approximately one year, as reported in a recent SEC Form 4 filing.

Summary

• David E.I. Pyott, a Director of Pliant Therapeutics, Inc. (PLRX), was granted 30,000 derivative securities in the form of stock options.
• The transaction date for this grant was June 5, 2025.
• The exercise price for these options is $1.61 per share.
• The options have an expiration date of June 5, 2035.
• The vesting schedule for these options is structured as follows: 25% vest on October 1, 2025; 25% vest on January 1, 2026; 25% vest on April 1, 2026; and the remaining 25% vest on the earlier of the one-year anniversary of the June 5, 2025 grant date or the next annual meeting of stockholders.
• Vesting is contingent upon Mr. Pyott's continued service as a Director to the Issuer through each respective vesting date or annual meeting.
• Following this transaction, Mr. Pyott beneficially owns 30,000 derivative securities.
• A Limited Power of Attorney was executed on June 5, 2025, appointing Keith Cummings, Johannes (Hans) Hull, Jennifer Woo, and Scott Peters to execute and file SEC forms on behalf of Mr. Pyott.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is generally a neutral to slightly positive event, as it aligns management's interests with shareholders. It is a standard compensation practice and does not inherently signal significant positive or negative operational news.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, as the options gain value if the company's stock price increases.
• The vesting schedule encourages the director's continued service and commitment to the company's long-term success.

Risks

• The value of the stock options is dependent on the future market price of Pliant Therapeutics' common stock, which could decline.
• The options are subject to vesting conditions, meaning the director must continue service to the company to fully realize the benefit of the grant.

Future Outlook

The vesting schedule of the stock options indicates an expectation of continued service from Director David E.I. Pyott to Pliant Therapeutics, Inc. through at least the one-year anniversary of the grant date or the next annual meeting of stockholders.

Management Comments

• The filing was signed by Jennifer Woo, attorney-in-fact, on behalf of David E.I. Pyott, indicating the delegation of filing responsibilities.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity transaction, common across all publicly traded companies. It reflects a standard practice of compensating directors with equity to align their interests with long-term shareholder value, particularly in the biotechnology sector where Pliant Therapeutics operates.

Corporate Governance

Related Party Transactions

• The grant of 30,000 stock options to David E.I. Pyott, a director of Pliant Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options represents potential future dilution if exercised, but also aligns the director's financial incentives with the company's stock performance.
• Director (David E.I. Pyott): Receives equity compensation, which is a significant component of executive and director pay, incentivizing long-term commitment and performance.

Next Steps

• The options will vest in tranches on October 1, 2025, January 1, 2026, and April 1, 2026, with the final tranche vesting on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Pliant Therapeutics, PLRX, stock options, insider transaction, Form 4, beneficial ownership, director compensation, equity compensation, SEC filing